Ethic Inc. Buys New Position in Charles River Laboratories International, Inc. $CRL

Key Points

• Ethic Inc. purchased a new stake in Charles River Laboratories International, Inc. valued at approximately $523,000 during the first quarter, acquiring 3,584 shares.
• Several institutional investors significantly increased their positions in CRL; for instance, Rothschild Investment LLC boosted their stake by 480% in the same quarter.
• Charles River Laboratories reported $3.12 EPS in its latest quarterly results, surpassing analysts' expectations of $2.50, with a revenue of $1.03 billion.

Ethic Inc. acquired a new stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 3,584 shares of the medical research company's stock, valued at approximately $523,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Dimensional Fund Advisors LP increased its stake in shares of Charles River Laboratories International by 30.0% in the first quarter. Dimensional Fund Advisors LP now owns 862,254 shares of the medical research company's stock worth $129,799,000 after purchasing an additional 198,750 shares in the last quarter. Vestmark Advisory Solutions Inc. boosted its holdings in Charles River Laboratories International by 77.4% in the 1st quarter. Vestmark Advisory Solutions Inc. now owns 41,820 shares of the medical research company's stock worth $6,295,000 after buying an additional 18,252 shares during the period. Public Sector Pension Investment Board boosted its holdings in Charles River Laboratories International by 113.7% in the 1st quarter. Public Sector Pension Investment Board now owns 13,659 shares of the medical research company's stock worth $2,056,000 after buying an additional 7,266 shares during the period. Nuveen LLC bought a new stake in Charles River Laboratories International during the 1st quarter valued at $18,538,000. Finally, Aigen Investment Management LP bought a new stake in Charles River Laboratories International during the 1st quarter valued at $231,000. Institutional investors own 98.91% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. JPMorgan Chase & Co. raised their price target on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. TD Cowen raised Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective on the stock in a report on Wednesday, May 14th. Barclays lifted their target price on Charles River Laboratories International from $155.00 to $165.00 and gave the company an "equal weight" rating in a report on Thursday, August 7th. Wall Street Zen cut Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research report on Sunday, August 17th. Finally, Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating in a research report on Wednesday, May 14th. Five analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $175.69.

Charles River Laboratories International Price Performance

Shares of CRL stock traded down $1.37 during trading hours on Wednesday, reaching $162.35. The stock had a trading volume of 46,168 shares, compared to its average volume of 1,251,560. The stock's fifty day simple moving average is $158.30 and its 200 day simple moving average is $148.64. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. Charles River Laboratories International, Inc. has a 12 month low of $91.86 and a 12 month high of $230.02. The firm has a market capitalization of $7.99 billion, a PE ratio of -122.07, a PEG ratio of 5.24 and a beta of 1.48.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its quarterly earnings data on Wednesday, August 6th. The medical research company reported $3.12 EPS for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The company had revenue of $1.03 billion during the quarter, compared to analyst estimates of $983.76 million. During the same period last year, the business earned $2.80 earnings per share. Charles River Laboratories International's revenue was up .6% compared to the same quarter last year. On average, equities research analysts predict that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Joseph W. Laplume sold 800 shares of the firm's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the sale, the executive vice president directly owned 24,116 shares of the company's stock, valued at $3,800,681.60. This trade represents a 3.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. 1.30% of the stock is owned by corporate insiders.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).